Health and productivity benefits of anti-PD-(L)1 agents for early-stage cancer treatment in Hungary
Investing in anti-PD-(L)1 agents for early-stage disease may not only increase the life expectancy and QALYs for patients in Hungary but also increase productive work years for both patients and caregivers in Hungary. In addition, it may also help to reduce metastatic disease treatments and cancer-related deaths.
Authors
- Máté Várnai (ORCID: https://orcid.org/0000-0002-8617-0371)
- Vivek Khurana
- K. Patterson (ORCID: https://orcid.org/0009-0009-4423-0098)
- Daniel Ladino
- R Aguiar-Ibáñez
- Éva Balogh
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Merck Canada Inc. (Canada) (CA)
- Health Economics and Outcomes Research (United Kingdom) (GB)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2026-02-17
- DOI
- https://doi.org/10.1080/13696998.2026.2626240
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00